Skip to main content
ONCOSIL MEDICAL LTD logo

ONCOSIL MEDICAL LTD — Investor Relations & Filings

Ticker · OSL ISIN · AU000000OSL3 ASX Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2026-02-02 Capital/Financing Update
Country AU Australia
Listing ASX OSL

About ONCOSIL MEDICAL LTD

https://www.oncosil.com

OncoSil Medical Ltd is a medical technology company focused on the development and commercialization of localized treatments for patients with unresectable cancers. The company's lead product, OncoSil, is a targeted radioactive isotope microparticle therapy designed to deliver a concentrated dose of beta radiation directly into solid tumors. It is primarily indicated for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. The device utilizes Phosphorus-32 microparticles administered via endoscopic ultrasound-guided fine-needle injection, providing a localized brachytherapy approach intended to reduce tumor volume and improve surgical resectability. OncoSil Medical holds regulatory approvals in multiple jurisdictions, including the CE Mark for use in the European Union and the United Kingdom, and continues to evaluate clinical applications for other solid tumor types.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - OSL 5 pages 18.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed securities issuance by Oncosil Medical Ltd, including the type of securities (options), number of securities, issue date, conditions, and regulatory compliance with ASX Listing Rules. It is a formal announcement of a capital raising or securities issuance event, specifically a placement or other type of issue. There are no financial statements or performance data, so it is not an Annual Report or Interim Report. It is not a report or presentation but an announcement of a capital/financing update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (6802 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2026-02-02 English
Capital Raising Presentation 29 pages 2.0MB
Investor Presentation Classification · 95% confidence The document is titled 'Capital Raising Presentation February 2026' and contains detailed information about the company's commercial activities, market opportunities, regulatory status, and strategic plans. It explicitly states it is a presentation prepared for investors and includes disclaimers about not being an offer for securities. The content focuses on business strategy, market potential, regulatory updates, and commercial progress rather than financial statements or audit results. There is no indication that this is a formal financial report like an Annual Report (10-K) or Interim Report (IR). It is also not a regulatory filing or announcement of voting results. The document is a detailed presentation aimed at investors about the company's capital raising and business prospects, fitting the definition of an Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2026-02-02 English
Update - Proposed issue of securities - OSL 8 pages 27.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed securities issue by Oncosil Medical Ltd. It includes specifics such as the type of securities, offer price, timetable, underwriting details, and use of funds. The document is an update to a previous announcement and focuses on the terms and conditions of a capital raising event. There are no financial statements or management discussion of results, nor is it a report or transcript. The content clearly relates to a capital/financing update regarding a securities issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (12,699 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2026-02-02 English
Trading Halt 2 pages 267.3KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from OncoSil Medical Ltd regarding a trading halt requested pending the release of an announcement about a capital raising. It is a short notice primarily informing the market about the halt and the expected timing of the subsequent announcement. There are no financial statements, detailed financial data, or report contents included. The document is an announcement related to capital raising activity but does not itself provide the capital raising update or financial details. According to the classification rules, such a document is best classified as a Capital/Financing Update (CAP) because it concerns a trading halt pending a capital raising announcement, which is a financing activity update.
2026-01-29 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 494.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 January 2026, titled 'Quarterly Activities & Cash Flow Report' for the quarter ended 31 December 2025 (Q2 FY26). It includes operational updates, financial highlights, and specifically references the Appendix 4C quarterly cash flow report attached to the announcement. The Appendix 4C is a standard Australian Securities Exchange (ASX) form for quarterly cash flow reporting. The document contains substantive financial data and analysis for the quarter, including cash flow statements, sales performance, and operational milestones. It is not merely an announcement of a report but includes the report itself and detailed financial information for the quarter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2026
2026-01-29 English
OncoSil delivers strong early clinical results in Turkiye 2 pages 255.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 30 January 2026 from OncoSil Medical Limited. It reports clinical results regarding the OncoSil™ device used in pancreatic cancer treatment, highlighting surgical resection rates and referencing clinical trial data and literature. The document is a public announcement of clinical outcomes and commercial strategy updates rather than a detailed financial report, regulatory filing, or management discussion. It does not contain financial statements, audit information, or detailed investor presentation content. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best as a Capital/Financing Update (CAP) type, as it relates to commercial progress and clinical results that support the company's market and capital strategy, which is typical for such announcements. Therefore, the classification is CAP with high confidence.
2026-01-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.